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Abstract
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy. Although novel emerging drugs are
available, the overall prognosis remains poor and new therapeutic approaches are required. PP2A phosphatase is a key
regulator of cell homeostasis and is recurrently inactivated in AML. The anticancer activity of several PP2A-activating
drugs (e.g., FTY720) depends on their interaction with the SET oncoprotein, an endogenous PP2A inhibitor that is
overexpressed in 30% of AML cases. Elucidation of SET regulatory mechanisms may therefore provide novel targeted
therapies for SET-overexpressing AMLs. Here, we show that upregulation of protein kinase p38β is a common event in
AML. We provide evidence that p38β potentiates SET-mediated PP2A inactivation by two mechanisms: facilitating SET
cytoplasmic translocation through CK2 phosphorylation, and directly binding to and stabilizing the SET protein. We
demonstrate the importance of this new regulatory mechanism in primary AML cells from patients and in zebrafish
xenograft models. Accordingly, combination of the CK2 inhibitor CX-4945, which retains SET in the nucleus, and
FTY720, which disrupts the SET-PP2A binding in the cytoplasm, significantly reduces the viability and migration of AML
cells. In conclusion, we show that the p38β/CK2/SET axis represents a new potential therapeutic pathway in AML
patients with SET-dependent PP2A inactivation.
Introduction
Acute myeloid leukemia (AML) is a highly hetero-
geneous fatal disease that results from the enhanced
proliferation and impaired differentiation of hemato-
poietic stem and progenitor cells1. For decades, che-
motherapy consisting of cytarabine and anthracyclines
has been the standard in AML care. Emerging drugs
show promising results2,3; however, the outcome for
AML remains poor and most patients ultimately relapse
and die from disease progression despite initial
sensitivity to chemotherapy. Patients older than 60 years
old, who represent the main group, are refractory to
cytotoxic intensive chemotherapy because of biological
disease-related factors, such as increased frequency of
adverse-risk cytogenetic and molecular features, and
secondary AML3. Moreover, they present comorbidities
that reduce their tolerance of intensive therapies, leaving
few treatment options in most cases1. Even in younger
patients the outcome is dismal. In patients ≤60 years old
complete remission is achieved in around 70%, but a
subset of patients relapse, depending on the prognostic
factors, and only 5–10% survive after relapse1,4. Current
efforts directed towards the genetic characterization of
AML have led to the development of new targeted
therapies, including FLT3, BCL2 and IDH1/2 inhibi-
tors5–10. However, monotherapy with these drugs does
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not result in durable responses. Thus, further research is
necessary to develop new personalized therapeutic
strategies for the treatment of this aggressive disease.
Reversible phosphorylation allows the cell to maintain
a proper homeostasis regulation; therefore, the balance
between kinases and phosphatases is essential to control
correct proliferation, apoptosis, and differentiation.
Many studies have analyzed the abnormal behavior of
protein kinases in AML, but the role of phosphatases
remains underexplored11,12. Protein phosphatase 2A
(PP2A) is a tumor suppressor that regulates several
essential cell functions and counteracts most of the
kinase-driven intracellular signaling pathways13. Pre-
vious results from our group and others showed that
PP2A inactivation is a recurrent event in AML, and that
its pharmacological activation by PP2A-activating drugs
(OP499, FTY720, and its analogues) effectively antag-
onizes leukemogenesis14,15. Furthermore, preclinical
studies show that these drugs have synergistic effects
with conventional chemotherapy and tyrosine kinase
inhibitors, opening new possibilities for personalized
medicine in AML16,17. Interestingly, the anticancer
activity of several PP2A-activating drugs depends on
their ability to interact with the endogenous PP2A
inhibitor SET, an oncoprotein overexpressed in ~30% of
AML patients and associated with poor outcome18,19.
Therefore, targeting SET allows PP2A to be reactivated
indirectly, avoiding toxicity problems related to the
direct activation of this complex holoenzyme. SET is a
multitask oncogenic protein involved in many cellular
processes20–23. However, despite the prognostic impact
of SET overexpression in both hematologic and solid
tumors, the mechanisms by which SET is regulated
remain poorly understood. We have previously reported
a novel multi-protein complex that activates SET tran-
scription in AML24. Here, we explore the post-
transcriptional regulation of SET, which may help us
to develop novel targeted therapies in AML patients
with PP2A inactivation and high expression of SET.
Using genetic and pharmacological approaches, we
found that p38β, one of the p38 family members whose
function is not well known, has a dual role in the reg-
ulation of PP2A activity in AML. p38β regulates SET
phosphorylation and intracellular localization through
the activity of casein kinase 2 (CK2). Furthermore, p38β
stabilizes the SET protein, facilitating its PP2A inhibi-
tory role. Importantly, we validated this mechanism
in vivo by demonstrating that the combination of the
CK2 inhibitor CX-4945, and the PP2A-activating drug
FTY720 significantly reduces the viability and migration
of AML cells. This novel mechanism may constitute the
basis for targeted therapy in AML patients with SET
overexpression.
Materials and methods
Patient samples
The study comprised peripheral blood mononuclear cells
(PB-MC) samples of 27 patients with AML at diagnosis
who stated an informed consent (Supplementary Table S1).
All patients were treated with standard induction che-
motherapy. High-dose cytarabine, and autologous or allo-
geneic stem cell transplantation, when possible, were used
as consolidation therapy. PB-MC samples of healthy
donors were used as controls. This study is part of a project
approved by the Comité Ético de Investigación Clínica,
Gobierno de Navarra (2018/32). The experiments con-
formed to the principles set out in the WMA Declaration
of Helsinki. AML patient sample cells (CD34+) were cul-
tivated in the semisolid medium MethoCult (StemCell
Technologies, Grenoble, France) supplemented with peni-
cillin G (100 U/ml) and streptomycin (0.1mg/ml). In the
medium, different concentrations of FTY720, CX-4945 and
combination were added. After 12–14 days growing at
37 °C in a 5% CO2 atmosphere, the present colonies were
counted at an inverted light microscope (Leica Biosystems,
Barcelona, Spain) using a grid (2700, StemCell).
In vitro kinase assay
Bacterially-expressed p38α or p38β (0.2 μg) were pre-
incubated with purified MKK6 (40 ng) and then incubated
with purified GST, GST-ATF2 or GST-SET (1 μg) in kinase
buffer (50mM Tris-HCl pH 7.5, 10mM MgCl2, 2mM
DTT, 0.1mM Na3VO4, 1mM PMSF and 10 μg/ml apro-
tinin and leupeptin) containing 100 μM cold ATP and 2μCi
of [γ-32P]ATP (3 000 Ci/mmol) for 40min at 30 °C. Reac-
tions were stopped by adding sample loading buffer and
boiling 5min. Proteins were resolved by SDS-PAGE,
stained with Coomassie, and analyzed by autoradiography.
Plasmids, siRNA, and transfection
siRNAs were from Ambion (Madrid, Spain): scramble
siRNA (#AM4635), MAPK11/p38β (#1:s11155 and
#2:11156), MAPK14/p38α (#1:s3586 and #2:s3585), and
CK2 (s3638). SET siRNAs were siSET#1 (#23-2506-2/4,
Eurofins, Ebersberg, Germany) and siSET#2 (#5883466,
Invitrogen). Due to the high efficiency obtained with
siRNAs #1 from p38α and p38β we used them for all
experiments. For silencing experiments, cells were trans-
fected using GenePulser XcellTM (Bio-Rad, Madrid,
Spain) with 300 V and 1000 μF. The shRNAp38β cloned
in the pINDUCER 11 (44.363 from Adgene, Teddington,
UK) was shRNA1: CACGTTCAATTCCTGGTTT and
shRNA2: GCGCCAGAAGGTGGCGGTGAAG.
General methodology
Details on general methodology as western blot, protein
immunoprecipitation, apoptosis, and MTS assay have
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been previously described14,18,19,24,25. Reagents and anti-
bodies used are displayed in Supplementary Tables S2 and
S3, respectively. Nuclear and cytoplasmic proteins were
extracted using the NE-PER nuclear and cytoplasmic
extraction kit (Thermo-scientific, UK) according to
manufactured instructions.
Cell culture and treatments
HL60, MOLM-13, and HEK293T cells were maintained
in RPMI-1640 (Invitrogen, UK) supplemented with 10%
FBS, penicillin G (100U/ml) and streptomycin (0.1 mg/
ml). Cell lines were grown at 37 °C in a 5% CO2 atmo-
sphere. Prior treatments, cells were plated at 100,000
cells/ml.
Immunofluorescence
100,000 cells were seeded on cover slips coated with
poly-L-lysine (Sigma, Madrid, Spain), fixed with 4% par-
aformaldehyde (Thermo-scientific) and permeabilized
with 0.1% Triton-X-100. After blocking with 5% FBS,
incubation with primary and secondary antibodies were
performed (Supplementary Table S3). Images were
acquired using a Confocal Scanning Laser Microscopy
Zeiss LSM 800 with ×63 immersion oil objective. Image
quantification was performed using Fiji software26. For
colocalization, the red, green and red-green colocalization
volumes (umÂ³) were quantified and referred to total cell
volume. For nuclear and cytoplasmic quantification, green
volume (umÂ³) was measured in the cytoplasm and the
nucleus and referred to total cell volume.
Phos-tag, immunoblot and λ-phosphatase treatment
10% acrylamide gels were prepared in the presence of
40 μM of Phos-tag (Fujifilm Wako, Neuss, Germany) and
20 μM of MnCl2. Proteins were transferred to a PVDF
membrane (Immobilon-P membranes, Millipore, Madrid,
Spain) using the Tank blotting system (Bio-Rad, Madrid,
Spain). As a control, an aliquot of the cell lysate (15 μg)
was incubated with 100 units of λ-phosphatase (Biolabs,
Spain) for 1 h at 30 °C in a shaking thermoblock.
Migration assay
Migration assay was performed in a 24-transwell
permeable plate with 8.0 μM pores (Corning Costar,
Madrid, Spain). The lower compartment contained RPMI
supplemented with 10% FBS. 500,000 treated cells were
seeded in the upper insert in medium without serum and
allowed to migrate for 3 h. The volume of the bottom well
was collected and mixed with perfect-count microspheres
(cytognos, Salamanca, Spain). The amount of viable
migrated cells was determined by flow cytometry,
counting 5000 microsphere-events and expressed as a
percentage of the control.
Zebrafish husbandry and embryo collection
Wild-type zebrafish (Danio rerio, AB strain), from the
Zebrafish International Resource Centre, were main-
tained in re-circulating tanks according to the standard
procedures. Adult fishes were maintained at 26 °C, with a
light/dark cycle of 14/10 h, and were fed twice daily,
once with dry flake food (Prodac, Italy) and another with
live Artemia salina (MC 450, Ive Aquaculture, USA).
Zebrafish embryos were maintained in egg water at 28.5 °C,
fed for 5 days with Novo Tom and with live Artemia
salina at 11 days of life. All experiments were performed
in compliance with the Guidelines of the European Union
Council for animal experimentation (86/609/EU).
Xenograft of human leukemia cells into zebrafish embryos
Wild-type zebrafish embryos at 48hpf were anesthe-
tized with 0.04% Tricaine (Sigma–Aldrich). Treated
leukemia cells were stained with red fluorescent CM-DiI
(Invitrogen) prior the injection. 50–75 labeled cells were
injected into the yolk sac of dechorionated zebrafish
embryos using a manual injector (Narishige). Fish with
fluorescently labeled cells appearing outside the
implantation area at 2hpi were excluded from analysis.
All other fishes were incubated at 35 °C for 72 h and
analyzed with the SteReo Lumar V12 stereomicroscope
with an AxioCam MR5 camera (Carl Zeiss, Germany).
Positive embryo colonization was considered when more
than five human leukemia cells were present outside the
yolk sac at 72hpx. Zebrafish colonization index was
calculated as the proportion of embryos colonized in the
treatment condition divided by the proportion of inva-
ded embryos in the control condition. Tumor growth
and proliferation were evaluated at 2 (reference) and
72hpx in a M205-FA fluorescence microscopy with a
DFC365FX camera (Fujifilm Leica). Proliferation index
(Fluorescence intensity medium value*fluorescence pixel
number) and area were measured with a Leica Appli-
cation Suite-X software.
Statistical analysis
Data represented are the mean of three independent
experiments ±S.D. Statistical comparisons were carried
out using the nonparametric method Kruskal–Wallis test
for more than two independent samples, followed by
Mann–Whitney U test to compared two groups when the
distribution was not normal (Shapiro-Wilk test p < 0,05).
Two-way ANOVA (Tukey’s multiple comparisons test)
when the distribution was normal (zebrafish proliferation
experiments). Chi-square statistical analysis was done for
the invasive potential calculation in zebrafish experi-
ments. Significance was considered when p < 0.05. For
AML patient samples tested, 20% decrease in viability was
chosen as the threshold as a response to the treatments.
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Results
p38β overexpression regulates PP2A activity in AML
through SET
To investigate the regulation of the SET oncoprotein in
AML, we performed a functional drug screen using
inhibitors of the main signaling pathways such as PI3K,
p38, JNK, and ERK in HL60 cells. Notably, only p38
inhibition using either SB203580 or PH797804 decreased
SET protein content without altering its mRNA levels
(Supplementary Fig. S1a, b), suggesting that SET was
regulated at post-transcriptional level. In fact, reduced
phosphorylation of HSP27, a downstream target of p38,
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Fig. 1 p38β is overexpressed in AML and its inhibition decreases SET protein levels, increasing PP2A activity. a HL60 and MOLM-13 cell lines
were treated with the p38 inhibitors SB203580 (2.5 µM) and PH797804 (250 nM) for 24 h. Protein expression for p-HSP27/HSP27 (p38 substrate) and
SET was analyzed by western blot. bMeasurement of PP2A activity after p38 inhibition by immunoprecipitation and phosphatase assay. c Silencing of
p38α and p38β with specific siRNA (50 nM for 48 h), and analysis of total protein by western blot. d Measurement of PP2A activity by
immunoprecipitation and phosphatase assay. e Western blot analysis of total protein in AML cell lines and AML patient samples, compared to
peripheral blood mononuclear cells (PB-MC). The results are corrected by the specific loading control and are expressed as fold-change of the
control, which are assigned a value of 1 and are mean values. Experiments were performed in triplicate four times. *p < 0.05.
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paralleled the decrease in SET protein levels (Fig. 1a).
Since SET is an important inhibitor of PP2A in AML, we
assessed the PP2A activity in the treated cells. As expec-
ted, both p38 inhibitors increased PP2A activity (Fig. 1b
and Supplementary Fig. S1a), suggesting that p38 inhibi-
tion affects PP2A activity in AML through SET. These
results were confirmed in MOLM-13, another AML cell
line (Fig. 1 and Supplementary Fig. S1c).
The p38 family has four members: p38α, p38β, p38γ,
and p38δ. As p38α and p38β are the main targets of
SB203580 and PH797804 at the tested concentra-
tions27,28, we focused on these two kinases. Knockdown
of p38α or p38β by specific siRNAs showed that
downregulation of p38β, but not p38α, significantly
decreased SET protein levels and increased PP2A
activity (Fig. 1c, d).
To explore the clinical relevance of this finding, we
assessed p38α and p38β expression in AML. The p38β
protein was highly expressed in 5 out of 7 AML cell lines
(71%), and in 23 out of 27 AML patient samples (85%);
whereas the p38α protein was almost equally expressed in
PB and AML specimens (Fig. 1e, Supplementary Fig. S2).
Correlation analysis indicated a positive co-expression
between SET and p38β protein levels, which was statis-
tically significant (R2= 0.376 p-value 0.0014). However,
no correlation was found between p38α and SET (R2=
0.004 p-value 0.7694). Quantitative analysis confirmed
that p38α was expressed at similar levels in PB and AML
cell lines (20–30 ng/100 μg total protein). However, p38β
was expressed at lower levels than p38α in HL60 and
MOLM-13 cells (2–3 ng/100 μg total protein), but it was
undetectable in PBMC (Supplementary Fig. S3). Taken
together, these results suggest that p38β is overexpressed
in AML and can regulate PP2A activity via SET.
p38β binds to and stabilizes SET in AML cells
We next focus on dissecting the mechanisms through
which p38β regulates the SET protein. Co-
immunoprecipitation experiments indicated that SET
bound to p38β in both HL60 and MOLM-13 cells, and to
a lesser extent, to p38α in HL60 cells (Fig. 2a). Immu-
nofluorescence analysis confirmed high expression and
cytoplasmic colocalization between p38β and SET, which
disappeared after silencing p38β, whereas p38α silencing
had no effect (Fig. 2b).
We hypothesized that p38β might phosphorylate SET.
Surprisingly, in vitro kinase assays showed no direct SET
phosphorylation either by p38β or p38α (Supplementary
Fig. S4a). Importantly, co-immunoprecipitation in HL60
cells treated with p38 inhibitors showed that SET-p38
interaction did not require kinase activation (Supple-
mentary Fig. S4b). For these reasons, we postulated that
p38β could regulate SET stability in a kinase-
independent manner. Treatment of cells with cyclo-
heximide demonstrated that SET is stable up to 48 h
(Supplementary Fig. S5a). Treatment of p38β-silenced
cells with cycloheximide resulted in a significant
decrease in SET (Supplementary Fig. S5b), suggesting
that p38β-SET interaction is critical for SET stability.
Besides, immunofluorescence analysis in samples from
AML patients that overexpress SET and p38β, such as
AML-23 or AML-25, demonstrated that both proteins
tend to associate and colocalized in the cytoplasm. In
contrast, samples from patients with no SET or p38β
overexpression, such as AML-24, showed minimal
colocalization (Fig. 2c, Supplementary Fig. S6a, b).
These results support the biological importance of SET-
p38β binding in AML, and suggest that p38β contributes
to cytoplasmic SET stability. Data from our group pre-
viously reported that SET protein stability is enhanced
through its binding to SETBP125. Here, we show that
SETBP1 and p38β colocalized along with SET in the
cytoplasm (Fig. 3a, Supplementary Fig. S7). Further-
more, we found SET-PP2Ac and PP2Ac-p38β colocali-
zation and interaction in AML cells (Fig. 3b). Taken
together, these results suggest that p38β acts as a SET
stabilizing protein, together with SETBP1, allowing SET
to inhibit PP2A in the cytoplasm.
p38β regulates CK2-mediated phosphorylation of SET and
facilitates its translocation to the cytoplasm
SET is mainly localized in the nucleus29, but AML cells
overexpressing SET showed strong cytoplasmic half-
moon-shape localization (Fig. 2b, c). It has been reported
in Alzheimer’s disease models that CK2 phosphorylates
Ser9 on SET, leading to its cytoplasmic translocation and
(see figure on previous page)
Fig. 2 p38β co-localizes with SET in AML cells. a Immunoprecipitation of SET, p38α and p38β with specific antibodies in HL60 and MOLM-13 cells.
Normal goat Ig was used as negative control b Knockdown of p38α and p38β with siRNA (50 nM for 48 h), using scramble siRNA as control, in HL60
and MOLM-13 cells. Immunofluorescence analysis of either p38α or p38β (red) and SET (green). Nuclei were stained with DAPI. Immunofluorescences
were visualized by confocal microscopy. Quantification table of colocalization fluorescence and green fluorescence (SET) in nucleus and cytoplasm.
Quantification analysis showed ~60% of SET-p38β colocalization in both cell lines, and only 12 and 29% of SET-p38α colocalization in MOLM-13 and
HL60, respectively. c Immunofluorescence analysis of p38β (red) and SET (green) in peripheral blood mononuclear cells (PB-MC) and the primary AML
patient samples AML-23 and AML-24. Nuclei were stained with DAPI. Quantification table of colocalization fluorescence. Immunofluorescences were
visualized by confocal microscopy. The results are expressed as mean values ± SEM. Experiments were performed in triplicate four times. *p < 0.05,
**p < 0.01. Scale bar represents 5 µm.
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inhibition of PP2A, resulting in tau phosphorylation30,31.
CK2 is overexpressed in most hematological tumors,
including AML32, and it is a target of p38 signaling33.
This data prompted us to postulate the potential role of
p38β in regulating CK2 and, consequently, the phos-
phorylation of SET in AML. Western blot showed that
overexpression of CK2 is a recurrent event in both AML
cell lines and patient samples (Fig. 4a, Supplementary
Fig. S2). First, we confirmed that CK2 phosphorylation is
indeed regulated by p38 in AML cells, as it is decreased
after p38α or p38β knockdown (Fig. 4b). Next, we
investigated whether p38β silencing or CK2 inhibition
using CX-4945 affects SET phosphorylation, by using
Phos-tagTM SDS-PAGE. Inhibition of CK2 and silencing
of p38β, but not p38α, substantially decreased the
phosphorylated forms of SET in AML cells (Fig. 4c,
Supplementary Fig. S8a). Interestingly, while both p38α
and p38β can potentially regulate CK2 phosphorylation,
only the inhibition of p38β affected SET phosphorylation
and SET interaction with CK2.
In order to confirm that p38β regulates PP2A activity,
we overexpressed p38β in HEK293T cells with the
pEFM-link-p38β plasmid. The ectopic increment of
p38β resulted in a significant increase in the phosphor-
ylation of CK2, accompanied with a reduction of PP2A
activity (Fig. 4d), suggesting that p38β is involved in CK2
activation and regulation of PP2A activity. To further
demonstrate that CK2 is crucial in the decrease of PP2A
activity produced by p38β overexpression, we inhibited
CK2 by adding CX-4945 (3.75 μM) for 24 h. CK2 inhi-
bition restored PP2A activity in cells overexpressing
p38β (Fig. 4d) suggesting that CK2 is an intermediate in
PP2A activity regulation by p38β. Additionally, to study
whether CK2 has a direct effect on PP2A regulation, SET
was silenced in both AML cell lines and then, the cells
were treated with CX-4945 to inhibit CK2. Inhibition of
CK2 in cells with reduced amount of SET had no effect
in PP2A activity in the AML cells tested (Fig. 4e), sug-
gesting that CK2-dependent inhibition of PP2A is
through SET.
Next, we treated AML cells with either CX-4945 or
CK2 siRNA, and found that CK2 inhibition or down-
regulation resulted in increased nuclear and decreased
cytoplasmic localization of SET (Fig. 5a, b, Supplementary
Fig. S8b, c), which increased PP2A activity (Fig. 5c). These
results were confirmed by immunofluorescence (Fig. 5d).
Furthermore, nuclear SET retention was accompanied by
enhanced p38β nuclear localization (Fig. 5e). Taken
together, our results show that p38β-dependent activation
of CK2 leads to SET phosphorylation, enhancing its
cytoplasmic localization and consequently reducing PP2A
activity (Fig. 5f).
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Inhibition of CK2 potentiates the anticancer activity of a
PP2A-activating drug on AML cells
We have shown that p38β contributes to the inactiva-
tion of PP2A in AML cells, which involves phosphoryla-
tion of SET by CK2. Therefore, we speculated that CK2
inhibition by CX-4945 could enhance the antileukemic
effect of the PP2A-activating drug FTY720 that binds
SET19. To test this idea, we first used immuno-
fluorescence to analyze the time-course of SET nuclear
retention after CK2 inhibition, which started at 4 h
(Supplementary Fig. S9). Accordingly, AML cells were
treated with CX-4945 for 4 h prior to FTY720 treatment.
The combined treatment significantly decreased cell via-
bility (Fig. 6a) and increased apoptosis (Fig. 6b) in AML
A
Actin
CK2
CK2/ Actin
PB
 M
C
1.0
H
EL
8.0
H
L6
0
7.5
M
O
LM
-1
3
2.0
KA
S1
2.9
K
56
2
7.2
K
Y
O
-1
7.2
M
EG
01
5.0
37
kDa
50
50
37
B
p-CK2               
CK2
Actin
sip38α
sip38β
p-CK2/CK2/Actin
Thr360/Ser362
kDa
MOLM-13HL60
- - +
- + -
- - +
- + -
C
E
D
PP
2A
 A
ct
iv
ity
(F
ol
d 
C
ha
ng
e)
CX-4945
- + - +
50
0
100
200
150
pEFM-p38β
+ +- -
*
*
p38β
SET
Actin
p-CK2               Thr360/Ser362
CK2
1.0 1.8* 1.0p-CK2/CK2/Actin 0.8
1.0 0.9 1.0SET/Actin 0.8
1.0 27** 1.1p38β/Actin 69**
CX-4945
- + - +pEFM-p38β
+ +- -
HEK293TMOLM-13
- - - + - -
- - + - - -
- - - - - +
+ - - - - -
sip38β
sip38α
CX-4945
λPP
SET
p-SET
PP
2A
 A
ct
iv
ity
(F
ol
d 
C
ha
ng
e)
HL60 MOLM-13
siSET#2
- - + +
50
0
100
200
300
150
250
350
50
0
100
200
300
150
250
350
siSET#1
CX-4945 + + - +
+ +
- -
- -- -
- -
- - + +
+ + - +
+ +
- -
- -- -
- -
*
*
ns
*
*ns
Actin
SET
SET/ Actin 1.0 1.1 0.9 0.6 0.4 0.4
37
kDa
50
37
1.0 1.0 0.4 0.6 0.2 0.3
siSET#2
- - + +siSET#1
CX-4945 + + - +
+ +
- -
- -- -
- -
- - + +
+ + - +
+ +
- -
- -- -
- -
HL60 MOLM-13
37
37
50
37
50
50
1.0 0.7* 0.2**1.0 0.7* 0.6*
Fig. 4 p38β regulates CK2-mediated phosphorylation of SET. a Western blot analysis of the CK2 protein in AML cells lines compared to
peripheral blood mononuclear cells (PB-MC). b Silencing of p38α and p38β with specific siRNA (50 nM for 48 h) and analysis of phospho- and total
CK2 by western blot in HL60 and MOLM-13 cells. c MOLM-13 cells treated with either siRNA for silencing p38α and p38β (50 nM for 48 h) or with the
CK2 inhibitor CX-4945 (5 µM, 24 h) and analyzed for phosphorylated forms of SET in SDS-PAGE with Phos-TagTM. A sample treated with λ phosphatase
(100 units, 1 h) was used as control. d Overexpression of p38β in HEK293T cells with 1 µg of pEFM link p38β plasmid or the empty plasmid with
lipofectamine 2000 and treated with CX-4945 (3,75 µM, 24 h). Analysis of p38β, SET and phospho- and total CK2 by western blot and PP2A activity.
e Silencing of SET with specific siRNA (50 nM for 72 h) and analysis of SET by western blot and PP2A activity in HL60 and MOLM-13 cells. The results
are corrected by the specific loading control and are expressed as fold-change of the control, which are assigned a value of 1 and are mean values.
Experiments were performed in triplicate four times. *p < 0.05 **p < 0.01.
Arriazu et al. Blood Cancer Journal            (2020) 10:3 Page 8 of 15
Blood Cancer Journal
A
MOLM-13
CX-4945 - + - +
GAPDH
LAMIN
SET
1.51.0SET/ Lamin
1.0 0.8SET/ GAPDH 0.4
1.5
1.0
1.0
- + - +
HL60
Cyto. Nuc. Cyto.Nuc.
37
kDa
75
50
37
B MOLM-13
siCK2 - + - +
GAPDH
LAMIN
SET
2.01.0SET/ Lamin
1.0 1.0SET/ GAPDH 1.1
1.5
1.0
1.0
- + - +
HL60
CK2
0.21.0CK2/ Lamin
1.0 0.8CK2/ GAPDH 0.8
0
1.0
1.0
Cyto. Nuc. Cyto. Nuc.
37
kDa
37
50
75
50
37
C
0
100
200
300
400
0
100
200
300
400
D
M
SO
C
X
-4
94
5
sc
ra
m
bl
e
si
C
K
2
* *
**
*
HL60
MOLM-13
P
P
2A
 a
ct
iv
ity
 (F
ol
d 
C
ha
ng
e)
 
% SET
HL60
Nucleus Cytoplasm
DMSO 49±0.14 51±0.2
CX-4945 70*±0.10 30*±0.10
scramble 56±0.5 44±0.5
siCK2 76*±0.5 24*±0.5
MOLM-13
Nucleus Cytoplasm
53±0.12 47±0.10
78*±0.12 22*±0.14
55±0.5 45±0.5
59±0.5 41±0.5
D
sc
ra
m
bl
e
si
C
K
2
C
X
-4
94
5
D
M
S
O
MOLM-13HL60
SET DAPI SET DAPI
SET DAPI SET DAPI
SET CK2 SET CK2
SET CK2 SET CK2
F
SET p38βC
X
-4
94
5
D
M
S
O
FT
Y
72
0
C
X
-4
94
5
+F
TY
72
0
SET p38β
SET+p38β
SET+p38β
SET p38βSET+p38β
SET p38βSET+p38β
E
Fig. 5 (See legend on next page.)
Arriazu et al. Blood Cancer Journal            (2020) 10:3 Page 9 of 15
Blood Cancer Journal
cells, being more effective than either single treatment
and having a synergistic effect (Supplementary Fig. 10a).
These effects correlated with increased PP2A activity
(Fig. 6c) and reduced cell migration ability (Fig. 6d).
Immunofluorescence analysis showed that the combined
treatment retained SET in the nucleus together with p38β,
and disrupted the SET-PP2Ac interaction (Fig. 6e), sup-
porting the mechanism proposed. We also evaluated the
combined treatment in AML primary patient samples.
According to availability, we treated patient-derived PB-
MC samples (Supplementary Table S1) with FTY720, CX-
4945 or both, and then performed MTS assays. When
there was enough sample, we also tested the colony for-
mation ability. We found decreased viability in 64% of the
samples treated with FTY720 (15/24), and in 90% of the
samples treated with CX-4945 (10/11). Importantly, all
five AML patient samples that were treated with both
drugs showed a significant decrease in cell viability
compared to either treatment alone (a representative case
shown in Supplementary Fig. S10b). Colony formation
ability was also reduced in the three AML patient samples
treated with both drugs that were grown in semisolid
medium (Fig. 6f, Supplementary Fig. S10c).
Finally, we validated the proposed mechanism in a
zebrafish xenograft model, a robust animal system to test
tumor cell behavior and drug response34–36. AML cells
were evaluated for in vivo proliferation and invasion
potential in zebrafish embryos upon treatment with
FTY720, CX-4945 or their combination, following the
scheme in Fig. 7a. Embryos were analyzed 2 h post-
xenograft (hpx) to confirm proper injection, and 72hpx
for proliferation and invasion. The combined treatment
significantly decreased the proliferation index compared
to both single treatments and the control (Fig. 7b), as well
as the tumor growth area in zebrafish embryos (Fig. 7c).
We also studied the colonization potential of treated AML
cells by analyzing the zebrafish larvae with invasion in the
tail, as illustrated in Fig. 7d. Quantifications demonstrated
that treatment with CX-4945 and FTY720 significantly
reduced zebrafish larvae with AML cell tail invasion
(Fig. 7e). To corroborate the importance of p38β in our
model, we injected zebrafish embryos with AML cells
expressing two different doxycycline inducible p38β
shRNAs (Fig. 7a). We found that p38β silencing decreased
the proliferation and colonization index of AML cells in
zebrafish embryos 72hpx (Fig. 7f, Supplementary Fig.
S11), supporting the functional importance of p38β
overexpression in AML cells. Taken together, our results
combining FTY720 with CK2 inhibitors or using p38β
shRNAs support the proposed new mechanism that reg-
ulates AML cell viability and migration.
Discussion
Here, we investigated the post-transcriptional regula-
tion of the SET oncoprotein, establishing that p38β
overexpression is a common event in AML that leads to
PP2A inactivation through its endogenous inhibitor SET.
Furthermore, we provide evidence that p38β, but not the
closely related p38α family member, controls the phos-
phorylation of SET by CK2, facilitating SET shuttling
from the nucleus to the cytoplasm. Besides, p38β also acts
as a SET stabilizing protein, facilitating PP2A inactivation.
We describe a novel molecular pathway of leukemogen-
esis with therapeutic potential in AML patients that show
SET-dependent PP2A inactivation, a subgroup with poor
prognosis that represent ~30% of all AML cases. PP2A is a
tumor suppressor, which regulates most of the kinase-
driven intracellular signaling pathways. Thus, by targeting
SET, this approach allows reactivating PP2A indirectly,
avoiding toxicity issues related to the direct activation of
this complex holoenzyme.
Mitogen-activated protein kinase (MAPK) cascades are
important signaling pathways used by eukaryotic cells to
transduce extracellular signals. Using chemical inhibitors
of several MAPKs, we found that only p38 inhibitors were
able to increase PP2A activity by decreasing SET protein,
suggesting post-transcriptional regulation of SET. The
p38 family is involved in many cellular processes, and
(see figure on previous page)
Fig. 5 CK2 inhibition retains SET in the nucleus. a Nuclear (Nuc.) and cytoplasmic (Cyto.) protein isolated from HL60 and MOLM-13 cells treated
with CX-4945 (5 µM, 24 h) and analyzed by western blot for SET localization. b HL60 and MOLM-13 cells treated with specific siRNA for CK2 (20 nM,
48 h). Nuclear (Nuc.) and cytoplasmic (Cyto.) proteins were isolated and analyzed by western blot for SET localization. c Measurement of PP2A activity
by immunoprecipitation and phosphatase assay. The results are expressed as fold-change of the control, which are assigned a value of 1 and are
mean values ± SEM. Experiments were performed in triplicate four times. *p < 0.05, **p < 0.01. d Immunofluorescence analysis of CK2 (red) and SET
(green). Nuclei were stained with DAPI. Immunofluorescences were visualized by confocal microscopy. Scale bar represents 5 µm. Quantification
table of green fluorescence (SET) in nucleus and cytoplasm. The results are expressed as mean values ± SEM. Experiments were performed in triplicate
four times. *p < 0.05, **p < 0.01. e Immunofluorescence analysis of p38β (red) and SET (green). Nuclei were stained with DAPI. Immunofluorescences
were visualized by confocal microscopy. Scale bar represents 5 µm. f p38β is able to activate CK2, which phosphorylates SET and, as consequence,
facilities SET trafficking to the cytoplasm, contributing to PP2A inactivation in AML cells. Moreover, p38β binds to SET in the cytoplasm, contributing
to its stability and leading to PP2A inactivation. Treatment with CX-4945 (CK2 inhibitor) retains SET in the nucleus, avoiding its phosphorylation.
FTY720 treatment disrupts the SET-PP2A biding which remains in the cytoplasm.
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plays a key role in the stress response37. Although p38α
and p38β share 70% in amino acid sequence homology,
they have different functions37,38 and differential reg-
ulatory mechanisms39. Nevertheless, the high expression
of p38α in most tissues, together with the results using
knockout mice deficient in p38α or p38β, suggests that
p38α is the dominant form, although functional redun-
dancy has been reported40. As a consequence, most stu-
dies have focused on p38α, and little is known about
p38β37. In this regard, we have elucidated an important
role of p38β in AML that has not been previously sug-
gested. p38β is widely expressed, but usually at low levels
in most tissues37, and it is not detected in monocytes,
macrophages, or neutrophils41. We found that upregula-
tion of p38β, but not p38α, is a common event in AML
cases that contributes to the SET-dependent inactivation
of PP2A in AML, pointing to a relevant role of p38β in
this aggressive disease.
It has been reported that PP2A can regulate
p38 signaling pathway, and that PP2A and p38 form
complexes in the cytoplasm in basal conditions; in fact,
p38 may act as scaffold protein for NMP and PP2A42–45.
However, the nature of their connection varies depending
on the context. Upon TNF-induced stress conditions in
endothelium-derived cell lines, p38 positively regulates
PP2A activity42, whereas under hypoxia and survival
conditions in colorectal cancer cell lines, PP2A negatively
regulates p38MAPK activity44. Here, we show for the first
time that p38β controls PP2A activity through the reg-
ulation of its endogenous inhibitor SET.
Pyridinyl-imidazole inhibitors have allowed the identi-
fication of many functions regulated by p38 beyond the
stress response. However, these compounds do not per-
mit us to distinguish functions mediated by p38β from
those regulated by p38α. Therefore, we used RNA inter-
ference to decipher the specific role of p38β in AML cells.
Our immunoprecipitation and immunofluorescence ana-
lysis support the notion that p38β interacts with SET in
AML cells, and knockdown of p38β, but not p38α,
decreases SET protein levels and enhances PP2A activity.
Moreover, we found that p38β binding stabilizes the SET
protein in the cytoplasm, demonstrating a new role for
p38β. We had previously demonstrated that SETBP1
binds to and stabilizes SET, facilitating PP2A inhibition25,
and this result has been confirmed in other reports46,47.
Here we further characterize this mechanism by showing
that p38β co-localizes with SET, SETBP1, and PP2A,
regulating PP2A activity in AML cells. Additional studies
will be needed to elucidate how the interplay among these
proteins regulates SET stability.
SET is mostly located in the nucleus where it regulates
DNA replication, chromatin remodeling, gene transcrip-
tion20, DNA repair21, migration22, and cell-cycle pro-
gression23. Here, we report a robust accumulation of SET
into the cytoplasm of primary and patient-derived AML
cells. Several studies in Alzheimer’s disease show that CK2
phosphorylates SET on Ser9, in the nuclear localization
signal, which is key for SET cytoplasmic localization and
inhibition of PP2A, leading to tau hyperpho-
sphorylation30,31,48. Here we demonstrate in AML cells
that p38β is involved in SET trafficking to the cytosol and
PP2A inactivation through the activation of CK2, and that
silencing of p38β but not p38α decreases CK2-dependent
phosphorylation of SET. Moreover, overexpression of
p38β decreased PP2A activity in a CK2-dependent man-
ner. Consistent with these findings, pharmacological
inhibition or silencing of CK2 increased the nuclear
localization of SET, as well as PP2A activity, without
altering total SET protein levels. Interestingly, in the
absence of SET, inhibition of CK2 has no effect in PP2A
activity, supporting the new mechanism described here. It
should be noted that CK2 overexpression has been asso-
ciated with poor prognosis in AML patients with normal
karyotype32,49. Thus, our results support a model in which
p38β overexpression activates CK2, which in turn phos-
phorylates SET, facilitating its trafficking to the cytoplasm
where it inactivates PP2A. Therefore, our study identifies
a novel p38β-CK2-SET signaling pathway in
(see figure on previous page)
Fig. 6 CX-4945 and FTY720 combination therapy induces apoptosis in AML cell lines and primary patient samples. HL60 and MOLM-13 cells
pretreated for 4 h with CX-4945 (5 µM) and then treated for 24 h with FTY720 (5 µM). a Cell viability was measured by MTS analysis. The results are
corrected by the DMSO control and are expressed as fold-change of the control, which are assigned a value of 1 and are mean values ± SEM. b FACS
analysis of apoptosis in HL60 and MOLM-13 cell lines stained with propidium iodide (PI) and Annexin V. The percentages of viable and apoptotic cells
are indicated. c PP2A activity analysis performed by immunoprecipitation and activity assay. d Migration of HL60 and MOLM-13 placed in the upper
well of a 8.0 μM transwell plate in RPMI without FBS. The lower chamber contained RPMI supplemented with 10% FBS. Migration assay was
performed for 3 h and then assessed for cell number using flow cytometry e Immunofluorescence analysis of SET (green) and PP2A (red) and
quantification table of % colocalization between red fluorescence (PP2A) and green fluorescence (SET) and % of green fluorescence (SET) in nucleus
and cytoplasm. Nuclei were stained with DAPI. Immunofluorescences were visualized by confocal microscopy. Scale bar represents 5 µm.
Experiments were performed in triplicate four times. *p < 0.05, **p < 0.01. f AML patient samples were cultured in semisolid medium and treated with
CX-4945 (5 µM) and FTY720 (4 and 8 µM), alone or in combination. Colony formation units (CFU) were counted 12 days after seeding. Graphs of
counted CFU represented as percentage of CFU related to the control, which are assigned the total CFU (100%) and are mean values ± SEM.
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leukemogenesis that mediates PP2A inactivation. Inter-
estingly, the same pathway would be probably activated in
AML cases with CK2 overexpression, opening new
insights into the role of CK2 in AML.
We validated the importance of this new pathway by
showing that the combination of CX-4945, which inhibits
CK2 allowing nuclear SET retention, and FTY720, which
disrupts SET-PP2A binding, is more effective in
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Fig. 7 CX-4945 and FTY720 combination therapy induces AML cell death in zebrafish xenograft models. In vivo proliferation and invasive
potential of HL60 and MOLM-13 cells upon treatment with FTY720, CX-4945 or the combination of both compounds were analyzed in a xenograft
zebrafish model. a Timing scheme for the xenografts of zebrafish embryos. b Measurement of proliferation index performed as fluorescence intensity
medium value* RF pixel, demonstrating cell proliferation of treated cells in the xenograft model. c Representative pictures of Tumor growth of HL60
treated cells in zebrafish embryos 2 hpx (reference fluorescence) and 72hpx. Scale bars represent 0.1 mm. d Representative pictures of zebrafish
embryos injected with MOLM-13 cells and treated with DMSO or combination of CX-4945 (1 µM) and FTY720 (1 µM), which show the cells that
migrated to the tail after the treatment mentioned. Magnified pictures on the bottom show the invasion of cells in the tail. Scale bars from whole
zebrafish picture represent 0.5 mm and from zoom 0.1 mm. e Quantification of the invasive potential of the injected cells upon drug treatment.
Quantification performed as colonization index: count of zebrafish embryos with invasion of cells migrating outside the yolk sac referred to the
control embryos (injection of DMSO treated cells). Hpx: hours post-xenograft. **p < 0.01, ***p < 0.001 vs. DMSO treated cells. f In vivo proliferation and
invasive potential of HL60 and MOLM-13 cells upon infection with shp38β pINDUCER11 treated with and without doxycycline in a xenograft
zebrafish model measured at 72hpx. **p < 0.01, ***p < 0.001 vs. control cells.
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decreasing viability and inducing apoptosis of AML cells
from patients than either single treatment. In vivo studies
using zebrafish xenografts as a preclinical model34 sup-
ported the importance of p38β in AML cells, and con-
firmed that the combination of CX-4945 and FTY720 is
more effective than either treatment alone at reducing
tumor growth, as well as impairing cell migration and
invasion. Consistent with our results, SET phosphoryla-
tion would allow its interaction with the GTPase Rac1 and
cytoplasm localization, where SET inactivates PP2A. In
fact, it has been reported that Rac1 stimulated signaling
required for efficient cell migration involves SET-
mediated inhibition of PP2A, and that cytoplasmic tar-
geting of SET inhibits Rac1-induced cell spreading and
migration22. Taken together, our in vivo results confirm
the value of targeting multiple components of the same
pathway, and support the use of zebrafish xenografts to
predict drug sensitivity for personalized treatments in
AML cases.
In conclusion, we have identified a new role of p38β
MAPK and CK2 in AML leukemogenesis. We show that
p38β overexpression is a recurrent event in AML cases
that contributes to PP2A inactivation by regulating the
SET oncoprotein through two mechanisms: (i) p38β
controls CK2-mediated phosphorylation of SET facil-
itating its cytoplasmic localization, and (ii) p38β binds to
and stabilizes SET in the cytoplasm. Furthermore, we
provide in vivo evidence of this mechanism by targeting
the same pathway at different levels. We show that a
combination therapy using the CK2 inhibitor CX-4945,
which retains SET in the nucleus, and FTY720, which
disrupts the SET-PP2A binding in the cytoplasm, re-
activates PP2A, reducing the viability of AML cells. Our
results therefore provide the rationale for using a com-
bination of PP2A-activating drugs and CK2 inhibitors as
a novel therapeutic option for treating a subgroup of 30%
AML cases characterized by SET-dependent PP2A
inactivation.
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